中欧和东欧国家多发性硬化症患者获得药物,护理和服务的机会:比较分析
Yoana Seitaridou1, Dominik Grega2, Sorin Paveliu3
1Department of Organization and Economics of Pharmacy, Faculty of Pharmacy, Medical University of Sofia, Sofia, Bulgaria.
Expert review of pharmacoeconomics & outcomes research
|April 16, 2025
概括
在中欧和东欧国家 (CEECs) 中,获得多发性硬化症 (MS) 治疗和护理的机会差异很大. 虽然疾病修饰疗法 (DMT) 得到补偿,但服务的差异凸显了公平获取战略的需要.
科学领域:
- 神经学 神经学
- 医疗保健服务研究 医疗服务研究
- 相对的有效性比较
背景情况:
- 多发性硬化症 (MS) 护理和治疗的可访问性在中东欧国家 (CEECs) 提出了挑战.
- 医疗保健系统的变化会影响患者的治疗结果和获得基本治疗的机会.
研究的目的:
- 为了比较六个中东欧国家对多发性硬化患者的疾病修饰治疗 (DMT),护理和服务的获取.
- 确定该地区多发性硬化患者在治疗可及性和医疗支持方面的差异.
主要方法:
- 在保加利亚,爱沙尼亚,波兰,罗马尼亚,塞尔维亚和斯洛伐克的医疗保健专家中进行了基于问卷的两部分调查.
- 数据收集时间为2022年12月1日至2023年4月1日的四个月.
主要成果:
- 在MS药物定价,补偿和医疗技术评估 (HTA) 的法律要求中存在显著差异.
- 尽管DMT的普遍补偿,波兰报告了最高的MS支出 (在2021年为1.71亿欧元).
- 保加利亚的治疗准入率最高 (84.21%),波兰和斯洛伐克的治疗准入率相当 (78.95%).
结论:
- 在被调查的中东欧国家/地区,针对多发性硬化患者的医疗保健服务存在差异.
- 有针对性的干预措施至关重要,以确保MS患者平等获得护理和服务.
- 需要进行进一步的研究,以制定有效的策略,以改善该地区MS护理的可访问性.
相关概念视频
01:11Secondary Healthcare System
Secondary healthcare is offered by a specialist, generally in hospitals or clinics for patients referred by primary healthcare providers. It occurs when a person has an illness or injury that requires specific medical care. Secondary care is often referred to as acute care. Secondary care can range from uncomplicated care to repair a minor laceration or treat a strep throat infection to more complicated emergent care, such as treating a head injury sustained in an automobile accident. Whatever...
01:15Methods of Documentation VI: Case Management Model
The case management model is a multidisciplinary approach that involves healthcare professionals from diverse disciplines, such as physicians, nurses, therapists, social workers, and pharmacists, working collaboratively to address the various needs of patients. Each healthcare professional brings unique expertise and perspectives, contributing to a more comprehensive understanding of the patient's condition and tailoring treatment plans accordingly.
For example, a patient with a chronic illness...
For example, a patient with a chronic illness...
01:27Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
01:09Bioequivalence of Drugs: Drugs with Multiple Indications
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each indication due to...
01:29Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...